DNMT3A and neoplasm: DNMT3A deletion also appears to enhance the anti-tumor effects of T-cells whether in the context of immune-checkpoint inhibition, chimeric-antigen receptor (CAR) T-cells, or allogeneic HSCT (64, 71, 72).